The Cost-effectivness of Donepezil Therap in Swedish patients with Alzheimer`s disease : a Markov model
Linus Jönsson, Peter Lindgren, Anders Wimo, Bengt Jönsson, Bengt Winblad
Bok Svensk 2003
| Utgitt | 2003
|
|---|---|
| Omfang | 11 s.
|
| Opplysninger | Abstract: This study compared the cost-effectivness of donepezil, a new cholinesterase inhibitor indicated for the treatment of mild-to-moderate probable Alzheimer`s disease (AD) with no treatment. A Markov state transition model was employed to simulate treatment cocts based on Swedish epidemiologic data.The Markov state used in the model were defined according to cognitive function, as assessedby the Mini-Mental State Examination.Data on costs and baseline transition probabilities were taken from the Kungsholmen Project, an observational, population-based study of person aged >_ 75 years in Sweden. Data on the treatment effect were taken from a clinical trial comparing donepezil to placebo over 24 weeks and were applied to the baseline transition probablities to assess the effect of treating the clinical manifestions of AD in Swedish patients. Also, a within-trial analysis was performed for comparison, using transititon probabliities taken from the clinical study. Both models were run for 5 years in half-year cycles, and both demonstrated various degrees of cost savings and improved effectiveness, as measured by increased time in nonnservere disease states. Thus donepezil had superior cost-effectiveness compared with no treatment.
|
| Emner |
